- Home
- CAPR vs SITC Comparison
CAPR vs SITC Comparison
Compare CAPR & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- SITC
- Stock Information
- Founded
- CAPR 2005
- SITC 1965
- Country
- CAPR United States
- SITC United States
- Employees
- CAPR N/A
- SITC N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- SITC Real Estate Investment Trusts
- Sector
- CAPR Health Care
- SITC Real Estate
- Exchange
- CAPR Nasdaq
- SITC Nasdaq
- Market Cap
- CAPR 600.7M
- SITC 603.6M
- IPO Year
- CAPR N/A
- SITC 1993
- Fundamental
- Price
- CAPR $11.15
- SITC $11.96
- Analyst Decision
- CAPR Strong Buy
- SITC Hold
- Analyst Count
- CAPR 6
- SITC 8
- Target Price
- CAPR $41.67
- SITC $35.25
- AVG Volume (30 Days)
- CAPR 3.3M
- SITC 569.8K
- Earning Date
- CAPR 05-13-2025
- SITC 05-07-2025
- Dividend Yield
- CAPR N/A
- SITC 4.35%
- EPS Growth
- CAPR N/A
- SITC 151.17
- EPS
- CAPR N/A
- SITC 10.32
- Revenue
- CAPR $17,363,588.00
- SITC $227,525,000.00
- Revenue This Year
- CAPR $78.79
- SITC N/A
- Revenue Next Year
- CAPR $158.07
- SITC $17.57
- P/E Ratio
- CAPR N/A
- SITC $1.15
- Revenue Growth
- CAPR N/A
- SITC N/A
- 52 Week Low
- CAPR $3.52
- SITC $10.46
- 52 Week High
- CAPR $23.40
- SITC $18.15
- Technical
- Relative Strength Index (RSI)
- CAPR 56.47
- SITC 47.78
- Support Level
- CAPR $10.04
- SITC $11.74
- Resistance Level
- CAPR $10.80
- SITC $12.05
- Average True Range (ATR)
- CAPR 1.07
- SITC 0.24
- MACD
- CAPR 0.20
- SITC -0.02
- Stochastic Oscillator
- CAPR 87.16
- SITC 42.27
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.